Landscapes / Companies
Shanghai AbelZeta Ltd. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
3 in Phase 2
1 in Phase 1
Next date
dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell, Phase 1 trial completes
Drugs
4
in active trials · 5 in all
Trials
5 active
6 since 2021
Drugs4
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Gene therapy substances |
AbelZeta |
Phase 1/2 | 31 Mar 2027Phase 1/2 trial completes | ||
| How it works | A gene therapy | ||||
| Next date | 31 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Relapsed/Refractory Large B-Cell Lymphoma | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Apr 2030Phase 1/2 trial completes | |||
| Next date | 30 Apr 2030 · Phase 1/2 trial completes | ||||
| Also tested for | Hepatocellular Carcinoma, Squamous Cell Lung Cancer | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Multiple Myeloma | ||||
| Open drug page | |||||
— |
Phase 1 | 31 Jan 2027Phase 1 trial completes | |||
| Next date | 31 Jan 2027 · Phase 1 trial completes | ||||
| Also tested for | Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer | ||||
| Open drug page | |||||
About
- No active trial
- Mesenchymal progenitor cells
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021